Cancer comes in many forms, but the abnormal cells tend to travel through the body via the bloodstream.
It’s only when the cancer cells form a mass that traditional diagnostic imaging techniques can identify the problem and shape a counterattack.
What if a new technology could identify cancer five to 12 months earlier? And what if this new technology could also offer clues on the most effective countermeasures?
That’s the vision of Triantafyllos (Fyl) Tafas, founder, CEO and director at QCDx (Quantitative Cell Diagnostix) in Farmington.
Cancer comes in many forms, but the abnormal cells tend to travel through the body via the bloodstream.
It’s only when the cancer cells form a mass that traditional diagnostic imaging techniques can identify the problem and shape a counterattack.
What if a new technology could identify cancer five to 12 months earlier? And what if this new technology could also offer clues on the most effective countermeasures?
That’s the vision of Triantafyllos (Fyl) Tafas, founder, CEO and director at QCDx (Quantitative Cell Diagnostix) in Farmington.
Tafas holds a Ph.D. in ecology and population biology from the University of Athens in Greece, where he developed a new prenatal screening for the Down Syndrome biomarker and introduced the first prenatal chromosomal abnormalities screening program for his home country.